Empagliflozin in Patients with Chronic Kidney Disease
Open accessThe DOI matches its Crossref record; 25 of the 26 references it cites were found in a registry or an index; 19 of the 28 sources its claims cite were checked for support.
Abstract
Trial of empagliflozin in a broad chronic kidney disease population.
Overview
CoChat Summary
TL;DR
Empagliflozin 10 mg daily reduced the risk of the composite of kidney disease progression or cardiovascular death in the EMPA-KIDNEY randomized trial of 6609 people with chronic kidney disease. Benefits were consistent with and without diabetes and across the eGFR range studied, with no clear increase in serious adverse events overall.
Key findings
- The primary composite outcome occurred in 432 of 3304 patients (13.1%) on empagliflozin versus 558 of 3305 (16.9%) on placebo; hazard ratio 0.72 (95% CI 0.64 to 0.82; P<0.001).
- All-cause hospitalizations were fewer with empagliflozin: 24.8 versus 29.2 hospitalizations per 100 patient-years; hazard ratio 0.86 (95% CI 0.78 to 0.95; P=0.003).
- There was no statistically significant effect on hospitalization for heart failure or cardiovascular death (4.0% vs 4.6%; hazard ratio 0.84, 95% CI 0.67 to 1.07; P=0.15) or death from any cause (4.5% vs 5.1%; hazard ratio 0.87, 95% CI 0.70 to 1.08; P=0.21).
- Empagliflozin slowed eGFR decline: the between-group difference in chronic slope was 1.37 ml/min/1.73 m² per year (95% CI 1.16 to 1.59), and urinary ACR was reduced by 19% (95% CI 15% to 23%).
Methods
- Multicenter, international, randomized, double-blind, placebo-controlled trial conducted at 241 centers in 8 countries; 6609 participants were randomized to empagliflozin 10 mg once daily or matching placebo.
- Eligible adults had CKD with eGFR ≥20 to <45 ml/min/1.73 m², or eGFR ≥45 to <90 ml/min/1.73 m² with urinary ACR ≥200 mg/g; patients with or without diabetes were eligible, and those with polycystic kidney disease or a kidney transplant were excluded.
- Primary analysis used intention-to-treat Cox regression adjusted for age, sex, prior diabetes, eGFR, urinary ACR, and region; key secondary outcomes were multiplicity-adjusted, and eGFR slope was assessed with shared parameter models.
Limitations
- The paper states that the lower-than-expected cardiovascular event rate reduced statistical power for secondary or tertiary cardiovascular outcomes.
- Evident from the text: the trial was stopped early for efficacy at an interim analysis, so follow-up was relatively short (median 2.0 years).
- Evident from the text: some subgroup estimates, especially for lower albuminuria strata, were limited by fewer primary outcome events.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
10 Valid · 0 Not valid · 4 Not checked · 40 Own results and interpretations
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A prespecified subgroup analysis from a trial of the SGLT2 inhibitor dapagliflozin in patients with CKD and a urinary ACR of at least 200 mg/g, found that kidney benefits extended to patients without diabetes”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Conclusions
What the sources say
- Supportedcites [7] Heerspink HJL Stefansson BV Correa-Rotter R Dapagliflozin in Patients with Chronic Kidney Disease N Engl J Med 2020 383 15 1436 1446 10.1056/NEJMoa2024816 32970396 source
The Abstract (p. 1437) specifies a urinary albumin-to-creatinine ratio of 200–5000 mg/g. Figure 2 identifies diabetes status as a prespecified subgroup, and the Discussion states that kidney-protective effects extended to participants with chronic kidney disease without type 2 diabetes. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [12] Wheeler DC Stefansson BV Jongs N Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial Lancet Diabetes Endocrinol 2021 9 1 22 31 10.1016/S2213-8587(20)30369-7 33338413 source
- Supportedcites [13] Staplin N Roddick AJ Emberson J Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials EClinicalMedicine 2021 41 101163 10.1016/j.eclinm.2021.101163 34765951 PMC8571171 source
The Results (Eligible trial characteristics) identify DAPA-CKD as a dapagliflozin trial in patients with CKD and urinary ACR of 200–5000 mg/g. The Results (Relative effects of SGLT-2 inhibitors) report that the effect on kidney disease progression in the CKD trial appeared similar with and without diabetes; the References identify the underlying DAPA-CKD work as a prespecified analysis. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The effect of SGLT2 inhibition on kidney disease progression or cardiovascular death seen in the present trial is quantitatively similar to that seen in two other large placebo-controlled trials in CKD populations.6,7”
§ Empagliflozin in Patients with Chronic Kidney Disease > Discussion
What the sources say
- Supportedcites [6] Perkovic V Jardine MJ Neal B Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy N Engl J Med 2019 380 24 2295 2306 10.1056/NEJMoa1811744 30990260 source
The Methods identify CREDENCE as a placebo-controlled trial in patients with type 2 diabetes and albuminuric CKD. Table 2 reports a hazard ratio of 0.70 for its primary composite of kidney disease progression or renal or cardiovascular death. This supports the citation’s role as one of the two earlier CKD trials; the paper does not itself compare its result with EMPA-KIDNEY. (LLM, conf=0.88)
- Supportedcites [7] Heerspink HJL Stefansson BV Correa-Rotter R Dapagliflozin in Patients with Chronic Kidney Disease N Engl J Med 2020 383 15 1436 1446 10.1056/NEJMoa2024816 32970396 source
The Efficacy Outcomes table reports that DAPA-CKD was a placebo-controlled trial in patients with chronic kidney disease and found a lower risk of the kidney-progression or cardiovascular-death composite with dapagliflozin (hazard ratio, 0.61). The cited paper supplies one of the two trial results; the statement that its effect is quantitatively similar to EMPA-KIDNEY is the citing authors’ comparison, not a finding attributed to this paper alone. (LLM, conf=0.90)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“or death from any cause (4.5% vs 5.1%)”
- Also stated in: § Primary and Secondary Outcomes · plain
“or on death from any cause (hazard ratio, 0.87; 95% CI 0.70 to 1.08; P=0.21)”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Primary and Secondary Outcomes · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The rates of serious adverse events were broadly similar in the two groups.”
- Also stated in: § Safety Outcomes and Adverse Events · hedged
“There was no apparent evidence that empagliflozin increased the incidence of serious adverse events overall, or in any particular MedDRA system organ class (Table S8).”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Results
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Safety Outcomes and Adverse Events · hedged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There were fewer hospitalizations from any cause in the empagliflozin group (0.86; 0.78 to 0.95, P=0.003)”
- Also stated in: § Primary and Secondary Outcomes · plain
“there were significantly fewer first and subsequent hospitalizations from any cause in the empagliflozin group (24.8 versus 29.2 hospitalizations per 100 patient years: hazard ratio, 0.86; 95% CI 0.78 to 0.95, P=0.003)”
- Also stated in: § Discussion · plain
“Risk of hospitalization for any cause was also reduced by 14%.”
§ Empagliflozin in Patients with Chronic Kidney Disease > Abstract > Results
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Primary and Secondary Outcomes · plain
17 more claims
Create a free account to see all 54 claims and every source verdict.
- It may state two separate claims as one. 24
- Probably not a substantial claim. 16
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The empagliflozintreated participants had lower risk of progression of kidney disease and lower risk of death from cardiovascular causes (HR 0.72 [95% CI 0.64-0.82];P < 0.001).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [115]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The empagliflozin-treated participants had lower risk of progression of kidney disease and lower risk of death from cardiovascular causes (HR 0.72 [95% CI 0.64-0.82];P < 0.001).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [128]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Dedicated kidney outcomes trials in people with CKD and type 2 diabetes have shown that the SGLT2 inhibitors empagliflozin, canagliflozin, and dapagliflozin have beneficial effects on slowing progression of CKD and CV outcomes in this population (139-141).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [141]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Furthermore, SGLT2i have been studied specifically among patients with CKD with or without T2D in 3 completed primary kidney outcome trials (CREDENCE[15], DAPA-CKD[16], and EMPA-KIDNEY[17]), which showed benefit for both a significant reduction in the primary kidney outcomes and cardiovascular outcomes [18,19].”
From Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection (2023) · cites this paper as [17]
The cited source says what the claim attributes to it.
In the citing paper
“The DAPA-CKD and FIDELIO trials enrolled patients with eGFR ≥25 mL/min/1.73 m2 and the EMPA-KIDNEY trial enrolled patients with eGFR ≥20 mL/min/1.73 m2; results demonstrated that dapagliflozin, finerenone and empagliflozin are effective and safe in these patients, although safety data are lacking for initiating therapy below these thresholds [16,17,22].”
From Glucagon-like peptide-1 receptor agonists in diabetic kidney disease: a review of their kidney and heart protection (2023) · cites this paper as [17]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493 · cited 1×
“…kidney disease with increased levels of albuminuria, large placebo-controlled trials have shown that renin-angiotensin system (RAS) inhibitors, 3–5 sodium-glucose cotransporter 2 (SGLT2) inhibitors, 6,7 and the non-steroidal mineralocorticoid receptor antagonist finerenone 8,9 all reduced the…”
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189 · cited 2×
“6,7 The CREDENCE trial of canagliflozin required all participants to have type 2 diabetes and a urinary ACR of at least 300 mg/g, and excluded patients with an eGFR of less than 30 ml per minute per 1.73 m 2 .”
InfluentialLewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618 · cited 3×
“…with an estimated GFR (eGFR) below 30 ml per minute per 1.73 m 2 or on how these benefits might vary among the wider range of patients with CKD. 7,12,13 This multicenter international randomized parallel group double-blind placebo-controlled clinical trial of EMPAgliflozin once daily to assess…”
InfluentialThe effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Cited by
Items 1,001–1,100 of 2,656
Chung, S. (2023) · Korean Journal of Medicine · doi:10.3904/kjm.2023.98.6.270 · Cited by 8
Papaetis, G. S. (2024) · Archives of Medical Science - Atherosclerotic Diseases · doi:10.5114/amsad/176658 · Cited by 11
Wang, Y., & Zhou, X. (2024) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-024-03631-7 · Cited by 7
Berezin, A. Е., & Berezina, T. A. (2024) · Journal of International Medical Research · doi:10.1177/03000605241227659 · Cited by 7
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H. H., Müller‐Wieland, D., Nauck, M. A., Wiesner, T., & Siegel, E. G. (2024) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-2166-6755 · Cited by 7
Edmonston, D. L., Mulder, H. S., Lydon, E. J., Chiswell, K., Lampron, Z. M., Shay, C. M., Marsolo, K. A., Jones, W. S., Butler, J., Shah, R. C., et al. (2024) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2024.04.011 · Cited by 8
Felix, N. S., Gauza, M. D. M., Teixeira, L., Guisso, M. E. S., Nogueira, A., Dagostin, C. S., Godoi, A., Ribeiro, S. A. G., Duque, J. C., Moura-Neto, J. A., et al. (2024) · Korean Circulation Journal · doi:10.4070/kcj.2023.0241 · Cited by 9
Monoclonal gammopathy of renal significance from the perspective of nephrologists
Park, K., & Kwon, S. H. (2024) · Blood Research · doi:10.1007/s44313-024-00027-5 · Cited by 6
An, J., Sim, J. J., Zhou, M. M., Zhou, H., Choi, S. K., Brettler, J. W., Ong‐Su, A. L., & Reynolds, K. (2024) · Journal of Clinical Hypertension · doi:10.1111/jch.14915 · Cited by 7
Liu, Y., Wang, Y., Chen, S., Bai, L., Li, F., Wu, Y. S., Zhang, L., & Wang, X. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175556 · Cited by 5
Antihyperglykämische Therapie bei Diabetes mellitus Typ 2 (Update 2023)
Clodi, M., Abrahamian, H., Brath, H., Schernthaner, G., Brix, J., Ludvik, B. H., Drexel, H., Saely, C. H., Fasching, P., Rega‐Kaun, G., et al. (2023) · Wiener klinische Wochenschrift · doi:10.1007/s00508-023-02186-4 · Cited by 9
“Während der medianen Nachbeobachtungszeit von 2 Jahren wurde durch die Gabe von Empagliflozin der Endpunkt (Progression der Niereninsuffizienz oder kardiovaskulärer Tod) signifikant gesenkt (HR 0,72; 95% CI: 0,6–0,82; p< 0,01) [32].”
BackgroundSodium-Glucose Cotransporter 2 Inhibitors in Older Patients with CKD
Bakker, W. M., Gansevoort, R. T., Yang, C., et al. (2024) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000000000466 · Cited by 5
Xiao, X., Ji, S., Zheng, T., Wang, T., Jiang, D., & Liu, F. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1468435 · Cited by 6
Mechanistic evaluation of ertugliflozin in patients with type 2 diabetes and heart failure
Lytvyn, Y., Scholtes, R. A., Boorsma, E. M., Sridhar, V. S., Kugathasan, L., Liu, H., Lovblom, L. E., Handoko, M. L., Mosterd, C. M., Floras, J. S., et al. (2025) · Physiological Reports · doi:10.14814/phy2.70275 · Cited by 7
Wang, M., & Zuo, L. (2025) · Cardiorenal Medicine · doi:10.1159/000545622 · Cited by 11
Datla, S., Albar, Z., Eaton, E., Porges, J., Nennstiel, M., Sullivan, C., Greene, L. A., Al-Kindi, S. G., Montgomery, E. A., Padiyar, A., et al. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101004 · Cited by 7
“EMPA-KIDNEY (Study of Heart and Kidney Protection with Empagli-flozin) similarly reported lower rates of death from CVD and CKD as well as reduced progression of kidney disease in the SGLT2i group compared with placebo [17].”
SGLT2 Inhibitors in Glomerulonephritis: Beyond Nephroprotection?
Vecchio, L. D., Peiti, S., Bella, G. P., & Locatelli, F. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14103533 · Cited by 12
Beyerstedt, S., Franco, M. L., Carlos, A. K. G., Arjona, J. E., Josefi-Rocha, G. R., Barbosa, B. S., Balby-Rocha, M. T. A., da Silva, A. F., Alves, T. M. R., Mariano, M. O., et al. (2025) · Stem Cell Research & Therapy · doi:10.1186/s13287-025-04358-7 · Cited by 7
“Preclinical studies and clinical trials have demonstrated that SGLT2 inhibitors are associated with lower rates of decline in estimated glomerular filtration rate (eGFR), reduced proteinuria, and consequently, a slowing in DKD progression [7, 8].”
Balancing Stone Prevention and Kidney Function: A Therapeutic Dilemma
Stepanova, N. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14113678 · Cited by 14
“Sodium–glucose cotransporter 2 (SGLT2) inhibitors, including empagliflozin, da-pagliflozin, and canagliflozin, are a well-established pharmacological class for renopro-tection in CKD, with their benefits in slowing renal decline widely recognized [198,199].”
Ono, R., & Falcão, L. M. (2025) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2025.02.007 · Cited by 11
Prognosis After >50% Decline in eGFR in Heart Failure Patients
Zahir, D., Elmegaard, M., Garred, C. H., Nouhravesh, N., Fosbøl, E. L., Jhund, P. S., McMurray, J. J. V., Petrie, M. C., Køber, L., & Schou, M. (2025) · JACC Heart Failure · doi:10.1016/j.jchf.2025.02.027 · Cited by 5
Long-term effects of SGLT2 inhibitors on arrhythmias: a systematic review and meta-analysis
Li, P., Chen, W., Chen, R., Zhang, H., Yu, Z., Yan, H., Du, B., & Yang, P. C. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1558367 · Cited by 8
Liew, A., Bavanandan, S., Hao, C., Lim, S. K., Prasad, N., Sahay, M., Susantitaphong, P., Roberts, V., Wijewickrama, E. S., Wong, M. G., et al. (2025) · Nephrology · doi:10.1111/nep.70030 · Cited by 7
IgA nephropathy: a paradigm shift in treatment strategies
Roberts, L. E., Jones, M., Barratt, J., & Selvaskandan, H. (2025) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000001105 · Cited by 7
Therapies in autosomal dominant polycystic kidney disease: beyond tolvaptan
Fang, C., Norouzi, S., & Garimella, P. S. (2025) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000001101 · Cited by 6
Bramlage, P., Vijayan, A., Varghese, T. P., Sadanandan, D. M., Lanzinger, S., & Rodriguez, C. F. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70010 · Cited by 7
What do clinical trials teach us about the pathophysiology of human IgA nephropathy?
Konda, R., Rajasekaran, A., & Rizk, D. V. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf144 · Cited by 6
Shi, C., Wang, X., Qin, S., He, A., Wu, X., Ke, Q., Shen, R., Wan, Y., Wang, L., Xiao, Y., et al. (2025) · Diabetologia · doi:10.1007/s00125-025-06519-y · Cited by 7
Fioretti, F., Butler, J., Udell, J. A., Jones, W. S., Petrie, M. C., Harrington, J., Mattheus, M., Bauersachs, J., Bayés‐Genís, A., Goodman, S. G., et al. (2025) · ESC Heart Failure · doi:10.1002/ehf2.15393 · Cited by 6
Aoyama, K., Okada, A., Kaneko, H., Azegami, T., Suzuki, Y., Meguro, S., Fujiu, K., Takeda, N., Morita, H., Node, K., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70255 · Cited by 6
Mottl, A. K., Scott, C. A. B., Green, J. B., Heerspink, H. J. L., Mann, J. F. E., McGill, J. B., Nangaku, M., Rosenstock, J., Rossing, P. R., Li, L., et al. (2025) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000928 · Cited by 8
Precision medicine in type 2 diabetes: targeting SGLT2 inhibitor treatment for kidney protection
Jansz, T. T., Young, K., Hopkins, R., McGovern, A. P., Shields, B. M., Hattersley, A. T., Jones, A. G., Pearson, E. R., Bingham, C., Oram, R. A., et al. (2025) · Diabetologia · doi:10.1007/s00125-025-06577-2 · Cited by 5
Mechanistic insights and clinical horizons of SGLT2 inhibitors in heart failure management
Vahid, S. S., Jahromi, M. S., Moukarbel, G. V., & Hill, J. W. (2025) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2025.11.004 · Cited by 6
Current treatment for diabetes: a holistic approach
Mourelatou, N. G., Kounatidis, D. C., Vallianou, N. G., Daniele, G., Dardano, A., & Rebelos, E. (2025) · HORMONES · doi:10.1007/s42000-025-00734-3 · Cited by 8
Dong, H., Chang, L., Tian, T., Shi, R., Yu, K., Wang, C., Liu, Z., Jin, Q., Wang, J., He, T., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1724965 · Cited by 9
Merolla, A., Valente, V., Basile, C., Benson, L., Cosentino, F., Dahlström, U., Guðbjörnsdóttir, S., Rovere, P. Q., Lund, L. H., Savarese, G., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02998-w · Cited by 5
Sriperumbuduri, S., Saravanan, P. B., Gupta, G., & Sanyal, A. J. (2025) · Kidney International Reports · doi:10.1016/j.ekir.2025.103757 · Cited by 12
Liu, Y., Fang, C., Chen, C., Yu, Y., Wang, J., Ye, L., Zhang, C., & Feng, Z. (2026) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2025.12.059 · Cited by 6
Meier, M., Cummings, J. L., Abdelsaid, M. A., Feliciano, J., Eusebe, J., Stirn, H., & Coucha, M. M. (2026) · Kidney Medicine · doi:10.1016/j.xkme.2026.101282 · Cited by 7
Cardio-Renal Syndrome: Review and New Perspectives
Martín, M., Fernández, M., Bacigalupe, L. P., & Rozado, J. (2026) · Journal of CardioRenal Medicine · doi:10.3390/jcrm2010004 · Cited by 7
Sex differences in cardiovascular-kidney-metabolic syndrome and new onset cardiovascular outcomes
Liu, L., Cai, A., Wu, K. C. H., Xu, A. M., Lip, G. Y. H., Cheng, Y., Cheung, B. M. Y., & Yiu, K. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156573 · Cited by 6
Ferrannini, G., Musella, F., Benson, L., Valente, V., Lindberg, F., Boccalatte, M., Cabrera, C. C., Dahlström, U., Lund, L. H., Stolfo, D., et al. (2026) · European Heart Journal - Quality of Care and Clinical Outcomes · doi:10.1093/ehjqcco/qcag063 · Cited by 6
Chronic kidney disease, complex conditions, and advancing therapeutics: new hope and challenges
Lees, J. S., Škoberne, A., Zhang, L., Wyatt, C., Fabian, J., Wang, A. Y.-M., Oni, L., & Levin, A. (2026) · The Lancet · doi:10.1016/s0140-6736(26)00653-7 · Cited by 6
Nohara, A. (2023) · Circulation Journal · doi:10.1253/circj.cj-23-0694 · Cited by 5
Pestka, D. L., Murphy, D. P., Huynh, P., Rechtzigel, J. A., Kjos, S., Ellich, L. M., Kaplan, A. N., Taylor, B. C., Atwood, M., Polsfuss, B. A., et al. (2024) · BMC Nephrology · doi:10.1186/s12882-023-03446-1 · Cited by 5
“…several recent studies have been published documenting the benefit of sodium-glucose co-trans-porter 2 inhibitors (SGLT2i) on reducing cardiovascular death and major adverse cardiovascular outcomes in patients with CKD, as well as decreasing the development or worsening of nephropathy [4–11].”
BackgroundPalomo‐Piñón, S., Aguilar-Alonso, J. A., Chavez-Iñiguez, J. S., Hernández-Arellanes, F. E., Mariano-Murga, J. A., Flores-Rodríguez, J. C., Pérez-López, M. J., Pérez, F. P., Treviño–Becerra, A., Guillén-Graf, A. E., et al. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1376115 · Cited by 9
Prediabetes and CKD: Does a causal relationship exist
Rico-Fontalvo, J. E., Soler, M. J., Daza-Arnedo, R., Navarro‐Blackaller, G., Medina-González, R., Yánez, T. R., Cardona-Blanco, M., Cabrales, J., Uparrela-Gulfo, I., & Chavez-Iñiguez, J. S. (2024) · Nefrología · doi:10.1016/j.nefro.2024.06.008 · Cited by 8
Sugawara, Y., Kanda, E., Hamano, T., Itano, S., Okada, H., Tomori, K., Watanabe, Y., Asakura, W., Isaka, Y., Iseki, K., et al. (2024) · Clinical and Experimental Nephrology · doi:10.1007/s10157-024-02514-6 · Cited by 6
“…AND "insufficiency"[All Fields] AND "chronic"[All Fields]) OR "chronic renal CANVAS Program [17] DAPA-CKD [18] EMPA-REG OUTCOME [19] EMPA-KID-NEY [20] CVD-REAL 3 [21] Nagasu, Kashihara (J-CKD-DB-Ex) [22] FIDELIO-DKD [ At the NKF-FDA-EMA workshop mentioned above, the validity of surrogate…”
BackgroundInfluentialManagement of patients with heart failure and chronic kidney disease
Wu, L., Rodríguez, M., Hachem, K. E., Tang, W. H. W., & Krittanawong, C. (2024) · Heart Failure Reviews · doi:10.1007/s10741-024-10415-9 · Cited by 6
“…CKD has also been demonstrated in the EMPA-KIDNEY trial that tested empagliflozin in patients with proteinuria and CKD with eGFR 20 to 45 ml/ min/1.73m 2 and showed that empagliflozin was not only associated with lower progression of CKD disease but was also associated with lower CV death [80].”
Targeting AXL cellular networks in kidney fibrosis
Grøndal, S. M., Blø, M., Nilsson, L. I. H., Rayford, A. J., Jackson, A., Gausdal, G., & Lorens, J. B. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1446672 · Cited by 6
What is new in the pathogenesis and treatment of IgA glomerulonephritis
Salvadori, M., & Rosso, G. (2024) · World Journal of Nephrology · doi:10.5527/wjn.v13.i4.98709 · Cited by 7
Minneci, C., Zucchini, M., Gonzini, L., Marini, M., Gori, M., & Maria, R. D. (2024) · International Journal of Cardiology · doi:10.1016/j.ijcard.2024.132906 · Cited by 5
Minutolo, R., Borrelli, S., Ambrosini, A., Amoroso, L., Aucella, F., Batini, V., Battaglia, Y., Bregoli, L., Cantaluppi, V., Cianciolo, G., et al. (2024) · Clinical Kidney Journal · doi:10.1093/ckj/sfae396 · Cited by 7
“In comparison with seminal RCTs with SGLT2i in patients with ND-CKD [2 , 3 ], the population enrolled in the present study is 3 to 6 years older, with more males and a prevalence of diabetes similar to the DAPA-CKD trial ( 68”
InfluentialAlbuminuria Prevalence in Fontan Patients: A Systematic Review and Meta-Analysis
Belle, H. V., den Eynde, J. V., Ciepłucha, A., Ladouceur, M., Martinod, K., Piérard, S., Coats, L., Jansen, K., Opotowsky, A. R., Craenenbroeck, A. H. V., et al. (2024) · Pediatric Cardiology · doi:10.1007/s00246-024-03736-x · Cited by 5
SGLT2 Inhibitors and Finerenone: A friendly Duo in the Treatment of Diabetic Kidney Disease?
Asirvatham, A. R., Asirvatham, A. J., & Mahadevan, S. (2024) · Journal of the Association of Physicians of India · doi:10.59556/japi.72.0759 · Cited by 7
“40 These renal outcome studies reemphasize the exclusive renal benefits of SGLT2i warranting their use in halting the progression of DKD. Obesity and dyslipidemia contribute to the worsening of DKD by accumulation of lipid in podocyte, causing injury and accelerating decline in eGFR.”
Lee, Y. S., Park, G., Lee, K., Jang, H. R., Lee, J. E., Huh, W., & Jeon, J. (2025) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2024-004876 · Cited by 6
Hsiao, C.-C., Chen, M., Liu, C. Y., Chan, C.-Y., Fang, Y.-W., Liou, H., & Tsai, M. (2025) · Clinical Kidney Journal · doi:10.1093/ckj/sfaf172 · Cited by 11
Zebrowska, A. M., & Borowiec, A. (2025) · Pharmaceuticals · doi:10.3390/ph18060857 · Cited by 5
“Sodium–glucose cotransporter-2 inhibitors (SGLT2i), originally used for glycemic control in type 2 diabetes mellitus (DM2), have shown pleiotropic effects, including nephroprotection and cardioprotection [6].”
Santos, G. L., dos Santos, C. F., Rocha, G. R., Calmon, M. S., Lemos, F. F. B., Silva, L. G., Luz, M. S., Pinheiro, S. L. R., Botelho, A. C., & de Melo, F. F. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i6.104706 · Cited by 11
Demir, M. E., Helvacı, Ö., Yıldırım, T., Merhametsiz, Ö., & Sezer, S. (2025) · Clinical Transplantation · doi:10.1111/ctr.70233 · Cited by 7
“Dedicated CKD-specific trials—DAPA-CKD, CREDENCE, and EMPA-KIDNEY, have further confirmed that SGLT-2 inhibitors significantly reduce the risk of GFR decline, end-stage renal disease, or death, even in patients without diabetes (Table 1) [16, 17, 23].”
Chan, J. S. K., Perone, F., Bayatpoor, Y., Tse, G., & Harky, A. (2023) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2023.2204188 · Cited by 7
Geist, B. K., Brath, H., Zisser, L., Yu, J., Fueger, B. J., Nics, L., Patronas, E., Kautzky‐Willer, A., Hacker, M., & Rasul, S. (2023) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-023-06256-7 · Cited by 5
Novel Drugs for the Management of Diabetes Kidney Transplant Patients: A Literature Review
Valencia-Morales, N. D., Cubillo, B. R., Loayza-López, R. K., de la Higuera, M. Á. M., & Sánchez-Fructuoso, A. I. (2023) · Life · doi:10.3390/life13061265 · Cited by 7
“Based on these study results, SGLT2i have emerged even as a new treatment option for CKD [73,74], considering that they are Life 2023, 13, 1265 11 of 24 indicated for the slow progression of the disease [22,75].”
BackgroundInfluentialEmerging Therapies and Advances in Sickle Cell Disease with a Focus on Renal Manifestations
Obadina, M. A., Wilson, S., Derebail, V. K., & Little, J. A. (2023) · Kidney360 · doi:10.34067/kid.0000000000000162 · Cited by 7
Diévart, F., Darmon, P., Halimi, J., Hadjadj, S., Angoulvant, D., Prévost, G., Delanaye, P., & Boivin, J. (2023) · Néphrologie & Thérapeutique · doi:10.1684/ndt.2023.25 · Cited by 12
Tabella, E., Correale, M., Alcidi, G., Pugliese, R., Ioannoni, S., Romano, M., Palmieri, G., Biase, M. D., Brunetti, N. D., & Iacoviello, M. (2023) · Clinics and Practice · doi:10.3390/clinpract13050090 · Cited by 5
Recurrent Immunoglobulin A Nephropathy after Kidney Transplant—An Updated Review
Han, H. S., Lubetzky, M., Anandasivam, N. S., Cox, R. A., & Lee, B. K. (2023) · Transplantology · doi:10.3390/transplantology4030016 · Cited by 11
Weingold, R., Zinman, B., Mattheus, M., Ofstad, A. P., Steubl, D., Wanner, C., & Inzucchi, S. E. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108628 · Cited by 6
Wu, M., Teng, T. K., Tsang, C. T., Chan, Y., Lee, C., Ren, Q. W., Huang, J., Cheang, I., Tse, Y.-K., Li, X., et al. (2023) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvad081 · Cited by 7
Gao, Q., Tan, N. C., Lee, M. L., Hsu, W., & Choo, J. C. J. (2023) · Scientific Reports · doi:10.1038/s41598-023-48427-4 · Cited by 6
Schumacher, C., Chorpash, A., Bolch, C., Eagan, K., Nimer, S., & Dril, E. V. (2023) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2902 · Cited by 6
2023 focused update of the 2021 ESC heart failure guidelines: Key messages for clinical practice
Tomasoni, D., Cannata, A. N., Adamo, M., & Metra, M. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14163 · Cited by 5
Ткачева, О. Н., Kotovskaya, Y. V., Bobkova, I. N., Шутов, А. М., Вадимовна, В. С., Ефремова, Е. В., Рунихина, Н. К., Eruslanova, K. A., Arutyunov, G. P., Batyushin, М. М., et al. (2024) · Russian Journal of Geriatric Medicine · doi:10.37586/2686-8636-1-2024-6-20 · Cited by 11
Медведева, Е. А., Usova, E., Solovyova, A. E., Dubinina, M. V., Вадимовна, В. С., Звартау, Н. Э., & Shlyakhto, E. V. (2024) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2024-5812 · Cited by 5
The management of heart failure in Sweden—the physician’s perspective: a survey
Ferrannini, G., Biber, M. E., Abdi, S., Ståhlberg, M., Lund, L. H., & Savarese, G. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1385281 · Cited by 7
“…guidelines HF with mildly reduced EF (HFmrEF) has class IIb level of evidence C recommendation for RASi, ARNi, beta-blockers and MRA, whereas in the 2023 update a class I level A recommendation for the SGLT2i empagli fl ozin and dapagli fl ozin was added, as also in HF with preserved EF (HFpEF)…”
BackgroundThe Impact of the Withdrawal of SGLT2 Inhibitors on Clinical Outcomes in Patients with Heart Failure
Nakagaito, M., Imamura, T., Ushijima, R., Nakamura, M., & Kinugawa, K. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13113196 · Cited by 7
“Given its pleiotropic effects, including its kidney-protective effects, the withdrawal of SGLT2i may also increase the risk of non-cardiovascular disease [9,10].”
BackgroundArabidze, G. G., & Мамедов, М. Н. (2024) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2024-5772 · Cited by 7
Aghakouchakzadeh, M., Hosseini, K., Haghjoo, M., Mirzabeigi, P., Tajdini, M., Talasaz, A. H., Jalali, A., Askarinejad, A., Kohansal, E., Hedayat, B., et al. (2024) · Pacing and Clinical Electrophysiology · doi:10.1111/pace.15038 · Cited by 5
Elliott, J., & Oyama, M. A. (2024) · Journal of Veterinary Pharmacology and Therapeutics · doi:10.1111/jvp.13472 · Cited by 8
Rastogi, A., Collins, A. K., Kelepouris, E., Kotzker, W. R., Middleton, J. P., Rajpal, M., Roy‐Chaudhury, P., & Chertow, G. M. (2024) · Journal of Primary Care & Community Health · doi:10.1177/21501319241259905 · Cited by 7
“2,12,13,31,32,37 There is a low risk of euglycemic diabetic ketoacidosis in some settings (patients who are fasting and/or have acute illness) that can be mitigated by temporarily withholding treatment.”
BackgroundToan, A. T. N., Phung, T. L., Dang, T. T. P., Alcusky, M. J., Amante, D. J., Nguyen, H. L., & Goldberg, R. J. (2024) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2024.2420654 · Cited by 5
“…survival in treating CKD with regardless of T2D status stage 2–4 with an eGFR of ≥20 to 45 ml per minute per 1.73 m 2 of body-surface area, or ≥45 to 90 ml per minute per 1.73 m 2 with a UACR ≥ 200 and an eGFR of 25–75 mL/min per 1.73 m 2 with a UACR of 200–5000 mg/g, respectively [10–12].”
InfluentialMontero, N., Oliveras, L., Martínez‐Castelao, A., Górriz, J. L., Soler, M. J., Fernández‐Fernández, B., Quero, M., García-Carro, C., García-Sancho, P., Goicechea, M., et al. (2024) · Nefrología · doi:10.1016/j.nefro.2024.11.002 · Cited by 5
Pesce, F., Vadalà, M., Almeida, E., Fernandez, B., Fouque, D. P., Małyszko, J., Schmidt-Ott, K. M., Stenvinkel, P., Wheeler, D. C., Seidu, S., et al. (2024) · Life · doi:10.3390/life14121668 · Cited by 8
de la Flor, J. C., Morales, B. C., Velasco, E. B., Hernandez, M. R., González-Mariño, R. Z., Tudero, C. R., Benites-Flores, I. R., Espinoza, C. V., Terrones, M. C., Guldris, S. C., et al. (2024) · Medicina · doi:10.3390/medicina60122096 · Cited by 8
Diabetes Mellitus in Kidney Transplant Recipients: New Horizons in Treatment
Sánchez-Baya, M., Bolufer, M., Vázquez, F., Alonso, N., Massó, E., Paúl, J., Coll-Brito, V., Taco, O., Antón-Pàmpols, P., Gelpi, R., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041048 · Cited by 6
Fong, J. M. N., Sia, C., & See, K. C. (2025) · Singapore Medical Journal · doi:10.4103/singaporemedj.smj-2025-012 · Cited by 5
Hansrivijit, P., Ortega-Montiel, J., Wexler, D. J., Patorno, E., & Paik, J. M. (2025) · Kidney Medicine · doi:10.1016/j.xkme.2025.101013 · Cited by 6
Biglari, S., Mischak, H., Beige, J., Latosińska, A., Siwy, J., & Banasik, M. (2025) · Biomolecules · doi:10.3390/biom15060809 · Cited by 10
Enhancing Heart Health: Expanding the Use of SGLT2 Inhibitors in Cardiovascular Disease
Mubeen, M., Sakarwala, A. S., Bijarani, A. I., et al. (2025) · Medicine Advances · doi:10.1002/med4.70014 · Cited by 5
Ndiaye, J. F., Nekka, F., & Craig, M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15031002 · Cited by 8
Advances in Clinical Cardiology 2022: A Summary of Key Clinical Trials
Savage, P., Cox, B., Shahmohammadi, M., Foster, J., & Menown, I. B. A. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02502-4 · Cited by 6
“EMPA-KIDNEY (Study of Heart and Kidney Protection With Empagliflozin) [83] randomised 6609 patients with impaired renal function (eGFR 20 to\45, or eGFR 45 to\90 plus urinary albumin-to-creatinine ratio[200) to empagliflozin versus placebo.”
BackgroundMuller, N., Busch, M., Gerdes, C., & Wolf, G. (2023) · Nephrologie aktuell · doi:10.1055/a-2055-3322 · Cited by 5
Milder, T. Y., STOCKER, S. L., Baysari, M. T., Day, R. O., & Greenfield, J. R. (2023) · Internal Medicine Journal · doi:10.1111/imj.16203 · Cited by 5
Ma, J., Lu, J., Shen, P., Zhao, X., & Zhu, H. (2023) · Renal Failure · doi:10.1080/0886022x.2023.2222847 · Cited by 8
“these results are inconsistent with those of the DaPa-cKD and eMPa-KiDNeY trials, suggesting renal protective effects of dapagliflozin and empagliflozin [72,73].”
ResultAlgoritmo de tratamiento de la diabetes mellitus tipo 2. RedGDPS 2023
Soidán, F. J. G. (2023) · Diabetes práctica · doi:10.52102/diabet/pract.2023.2.art2 · Cited by 5
Kim, J. H., Lyu, Y. S., Kim, B., Kim, M. K., Kim, S. Y., Baek, K., Song, K., Han, K., & Kwon, H. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15565 · Cited by 5
Miyazaki, M., Nakano, M., Takahashi, H., Isaka, Y., & Hiura, Y. (2024) · American Journal of Case Reports · doi:10.12659/ajcr.943945 · Cited by 7
Morello, C. M., Awdishu, L., Lam, S., Heman, A., & Bounthavong, M. (2024) · Kidney360 · doi:10.34067/kid.0000000597 · Cited by 7
SGLT2 inhibition, glucose transport and peritoneal dialysis: Finding the sweet spot
Sridhar, V. S., & Fraser, D. J. (2023) · Peritoneal Dialysis International · doi:10.1177/08968608231161178 · Cited by 5
“Importantly, as suggested by pre-specified analyses of EMPAKIDNEY, there does not appear to be an attenuation of kidney protective effects even at low eGFR sub-groups.(1) Studies in participants with CKD and preserved GFR demonstrate that SGLT2 inhibition causes an initial transient decrease in eGFR of approximately 5…”
MethodWell-Conducted Real-World Evidence Studies Can Complement Essential Evidence From Clinical Trials
Patorno, E. (2024) · Circulation · doi:10.1161/circulationaha.124.069220 · Cited by 5
Metadata
- Authors
- The EMPA-KIDNEY Collaborative Group
- Corresponding author
- The EMPA-KIDNEY Collaborative Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2023-01-12
- Volume
- 388
- Issue
- 2
- Pages
- 117-127
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC7614055
- OpenAlex
- W4308183941
- Cited by
- 2,754
- References
- 26
- Citations by year
- 2026: 727 · 2025: 759 · 2024: 734 · 2023: 520
- FWCI
- 321.13
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion, cc-by-nd)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion, cc-by-sa)
- Docusalut (Conselleria de Salut i Consum del Govern de les Illes Balears) (submittedVersion, cc-by-nd)
- Hispana (submittedVersion, cc-by-nd)
- Archivio Istituzionale della Ricerca - Università degli Studi della Campania "Luigi Vanvitelli" (submittedVersion)
- CINECA IRIS Institutial Research Information System (University of Genoa) (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Archivio Istituzionale della Ricerca - Università Vita-Salute San Raffaele (submittedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Bristol Research (University of Bristol) (submittedVersion)
- Explore Bristol Research (submittedVersion)
- CINECA IRIS Institutional Research Information System (University of Bari Aldo Moro) (submittedVersion)
- Funders
- Boehringer Ingelheim
- Eli Lilly and Company
- NIHR Biomedical Centre, Oxford
- Health Data Research
- Medical Research Council (MC_UU_00017/3 & MR/R007764/1)
- Kidney Research UK (MR/R007764/1)
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- empagliflozin, chronic kidney disease, kidney disease progression, cardiovascular mortality, heart failure hospitalization, SGLT2 inhibitors, EMPA-KIDNEY trial, estimated glomerular filtration rate, diabetes mellitus
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Benzhydryl Compounds, Cardiovascular Diseases, Creatinine, Diabetes Mellitus, Type 2, Glomerular Filtration Rate, Glucosides, Humans, Kidney, Disease Progression, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.